

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 12, 2025

Recombinant Anti-CD8 alpha antibody [EPR22483-288]

RRID:AB_3068617

Type: Antibody

Proper Citation

(Abcam Cat# ab245118, RRID:AB_3068617)

Antibody Information

URL: http://antibodyregistry.org/AB_3068617

Proper Citation: (Abcam Cat# ab245118, RRID:AB_3068617)

Target Antigen: CD8 alpha

Host Organism: Rabbit

Clonality: recombinant monoclonal

Comments: Applications: IHC-P, Flow Cyt, IP

Antibody Name: Recombinant Anti-CD8 alpha antibody [EPR22483-288]

Description: This recombinant monoclonal targets CD8 alpha

Target Organism: human

Clone ID: EPR22483-288

Antibody ID: AB_3068617

Vendor: Abcam

Catalog Number: ab245118

Record Creation Time: 20231110T031029+0000

Record Last Update: 20240725T053455+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-CD8 alpha antibody [EPR22483-288].

No alerts have been found for Recombinant Anti-CD8 alpha antibody [EPR22483-288].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Chen Z, et al. (2024) YTHDF2-mediated circYAP1 drives immune escape and cancer progression through activating YAP1/TCF4-PD-L1 axis. iScience, 27(2), 108779.

Deng S, et al. (2024) ITPRIPL1 binds CD3 ζ to impede T cell activation and enable tumor immune evasion. Cell, 187(9), 2305.

Chen S, et al. (2024) Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance. NPJ precision oncology, 8(1), 159.

Wang X, et al. (2024) Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer cell, 42(10), 1729.